Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-LEOPARD: lenvatinib plus hepatic arterial cisplatin before resection for biologically borderline resectable hepatocellular carcinoma
jRCT1031260517Phase 2Recruiting
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and cisplatin in hepatocellular carcinoma (HCC). Primary endpoint: Recurrence within 1 year after resection. Started Sep 2026; status: recruiting.
02
Drugs
lenvatinibcisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1031260517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260517.